Just now, the experimental results came out.

According to experimental results, the therapeutic effect of this new anti-hepatitis B virus drug reaches A+++, which is more than ten times better than the common anti-HBV drugs on the market.

Lang Yongfeng was very excited.

Immediately reported to Liang Shiqing, the president of Tianfeng Zhengda.

President Liang Shiqing is the granddaughter of Liang Jianguo, the founder of Thailand Zhengda Group, and is also the owner of another listed pharmaceutical company in China Biopharmaceuticals.

Liang Shiqing, who was in Xiangjiang, was very excited to hear this and said applaudingly: "Well, you did a good job. Thank you for your hard work. I will remember you a merit!"

Lang Yongfeng: "Thank you, Mr. Liang."

Liang Shiqing hung up the phone and took out her notebook to check the experimental data sent by Lang Yongfeng.

Sitting opposite Liang Shiqing were her two senior assistants, one of whom was a fat woman wearing glasses asked, "Mr. Liang, what's going on?"

Liang Shiqing quickly browsed the experimental data and then looked at the results directly.

When I saw the evaluation data, my face was filled with excitement.

"They just developed a new anti-hepatitis B drug. According to the experimental results, it has significant efficacy on hepatitis B virus, including hepatitis B tumors, which are much more effective than targeted drugs such as tenofovir, lamidofuridine, and adefovir."

The two assistants were also surprised when they heard this, "Is it true?"

Liang Shiqing: "Well! It's true."

After Liang Shiqing finished speaking, she immediately got up and went to the next room and called her father to report the good news.

Liang Shiqing's father knew the cause and effect of this incident. He said happily: "Let them speed up the research, it must be faster than there!"

Liang Shiqing: "I know..."

Just as Liang Shiqing and her daughter were dreaming of making a fortune with this new drug, they didn't know that three international pharmaceutical factories also obtained experimental data.

Research is also being stepped up at this time.

Those who plan to steal data from the universe will sell more information.

...

Two days later on the morning of September 29th.

Georgia, USA.

Huanyu Bio and two local CRO companies in the United States jointly issued a statement that HIV-specific drugs successfully passed the second phase of the window experiment.

The FDA subsequently issued a statement saying that it had received their "special assessment agreement" application form.

After the second phase of the clinical phase is over, a special evaluation protocol is conducted - Special Protocol AssessmentSpeci, referred to as "SPA".

This is used to clarify the design of the Phase III clinical trial, the end time of the trial, and various other factors.

This is also the key to the third phase clinical trial.

The US government has tried to suppress the news for many reasons, but HIV, as an epidemic virus, has as many as 37.9 million infected people worldwide, and the number of confirmed cases in the United States alone is more than 700,000, and in fact, there are more people.

Such a big thing, the US government will suppress it once, and it will be impossible for it to suppress it again.

In the end, the New York Times and the Wall Street Journal and other major newspapers reported one after another.

Subsequently, many international media such as the Financial Guardian, Mirror, Yomiuri News reported on this.

Soon the news spread all over the world.

Countless HIV-infected people are excited about it.

Because this is by far the only drug that is said to be a complete cure for HIV.

At the same time, many people did not notice that Universal Biologics, a new class I drug and three new class II drugs, successfully passed the first and second phase clinical trials in the United States and Europe respectively.

The world's pharmaceutical industry is ushering in a huge change.

...

It's October.

Huanyu Bio has launched a total of six bio ointments.

These ointments have particularly good effects on a series of skin diseases such as herpes, pustules, suppurative bacteria infections, ichthyosis, folliculitis, scleroderma, and psoriasis.

In addition, Huanyu Bio has launched several biological ointments for rheumatism and pain.

The reason for introducing ointment was a last resort.

Because it took a long time to go from research and development to market a new drug, Zhou Wen chose a ointment after weighing the trade-offs for many days.

Because although ointment is much worse than enteric-coated drugs in terms of efficacy, its advantage lies in the simplest drug review. Just get the patent done. From research and development to market, it can be done in at most 1 to 2 years.

It only took 10 months for their biological ointment to treat rheumatism and pain from research and development to market.

Of course, this ointment was also carefully studied by Zhou Wen after spending several days.

The formula containing biological nerve repair agents has obvious therapeutic effects on rheumatism and pain.

Of course, there is definitely no immediate effect as enteric-coated drugs or injected drugs!

Just as Universal Biotech began to make efforts in the pharmaceutical market, Anqimei Biotechnology, on the other hand, was also in the cosmetics market.

As a dark horse in the Chinese cosmetics industry, Anqimei used its strong product strength to explain what strength is to the majority of beauty lovers.

On October 1, Anqimei Biotechnology held a grand brand launch conference at the Jinling International Exhibition Center.

At this press conference, a total of two products were launched.

Bio-hair fluid.

Biosunscreen.

Under the attention of everyone, Mu Anqi explained two black technology cosmetics to the guests.

Many guests on the scene were so surprised that they couldn't stop after listening to the explanation.

Especially hair loss.
Chapter completed!